PE22998A1 - Ciclopeptolidos - Google Patents

Ciclopeptolidos

Info

Publication number
PE22998A1
PE22998A1 PE1996000830A PE00083096A PE22998A1 PE 22998 A1 PE22998 A1 PE 22998A1 PE 1996000830 A PE1996000830 A PE 1996000830A PE 00083096 A PE00083096 A PE 00083096A PE 22998 A1 PE22998 A1 PE 22998A1
Authority
PE
Peru
Prior art keywords
alpha
methyl
amino
replaced
substituted
Prior art date
Application number
PE1996000830A
Other languages
English (en)
Inventor
Michael Dreyfuss
Theodor Fehr
Carolyn Ann Foster
Dieter Geyl
Berndt Oberhauser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE22998(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9523744.2A external-priority patent/GB9523744D0/en
Priority claimed from GBGB9604406.0A external-priority patent/GB9604406D0/en
Priority claimed from GBGB9613990.2A external-priority patent/GB9613990D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE22998A1 publication Critical patent/PE22998A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungal isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)

Abstract

SE REFIEREN A COMPUESTOS DE FORMULAS (I) e (Ip`), ENTRE OTROS, EN DONDE LAS UNIONES "A-Y" e "A'p-Yp" SON ENLACES ESTER; "A" ES ACIDO GLICOLICO PREFERENTEMENTE ALFA-SUSTITUIDO POR METILO; "A'p" ES ACIDO BUTIRICO SUSTITUIDO CON ALFA-HIDROXI, EL CUAL ESTA GAMMA SUSTITUIDO POR (VI) o (VII); "B Y Bp" SON ACIDO OCTANOICO SUSTITUIDO CON ALFA-AMINO-GAMMA-METILO; R1 Y R1p SON HIDROGENO o METILO; "C" Y "Cp" SON TRIPTOFANO O N-METIL TRIPTOFANO; "X" Y "Xp" SON ACIDO CARBOXILICO C2-C14 SUSTITUIDO CON ALFA-AMINO; "Y" E "Yp" SON ACIDO CARBOXILICO DE C2-C10 SUSTITUIDO CON ALFA AMINO o N-METIL-ALFA-AMINO, EN DONDE ALFA-AMINO PREFERENTEMENTE ES ALA o VAL. TAMBIEN SE REFIEREN A LOS PROCEDIMIENTOS DE PREPARACION DE LOS CICLOHEPTAPEPTOLIDOS. ESTOS COMPUESTOS SON INHIBIDORES DE LA EXPRESION DE LAS MOLECULAS DE ADICION CELULAR (ICAM-1, VCAM-1 Y E-SELECTINA) QUE REGULAN LA MIGRACION DE LEUCOCITOS, SIENDO UTILES PREFERENTEMENTE EN EL TRATAMIENTO DE CONDICIONES INFLAMATORIAS Y AUTOINMUNES MEDIADAS POR EL FACTOR DE NECROSIS TUMORAL (TNF ALFA), TALES COMO CHOQUE SEPTICO, ARTRITIS REUMATOIDE O NEURODEGENERACION MEDIADA POR EL SISTEMA INMUNE (POR EJEMPLO EN EL SIDA), ENTRE OTROS
PE1996000830A 1995-11-21 1996-11-19 Ciclopeptolidos PE22998A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9523744.2A GB9523744D0 (en) 1995-11-21 1995-11-21 Organic compounds
GBGB9604406.0A GB9604406D0 (en) 1996-03-01 1996-03-01 Organic compounds
GBGB9613990.2A GB9613990D0 (en) 1996-07-04 1996-07-04 Organic compounds

Publications (1)

Publication Number Publication Date
PE22998A1 true PE22998A1 (es) 1998-05-12

Family

ID=27267982

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000830A PE22998A1 (es) 1995-11-21 1996-11-19 Ciclopeptolidos

Country Status (27)

Country Link
US (1) US6011136A (es)
EP (1) EP0866801B1 (es)
JP (1) JP3463691B2 (es)
KR (1) KR19990071533A (es)
CN (1) CN1125079C (es)
AR (1) AR012286A1 (es)
AT (1) ATE240972T1 (es)
AU (1) AU712900B2 (es)
BR (1) BR9611619B1 (es)
CA (1) CA2237157C (es)
CO (1) CO4770985A1 (es)
CZ (1) CZ154998A3 (es)
DE (1) DE69628323T2 (es)
ES (1) ES2200079T3 (es)
HU (1) HUP9903810A3 (es)
IL (1) IL124310A0 (es)
MX (1) MX9804048A (es)
MY (1) MY115877A (es)
NO (1) NO982280L (es)
NZ (1) NZ322909A (es)
PE (1) PE22998A1 (es)
PL (1) PL186010B1 (es)
RU (1) RU2171260C2 (es)
SK (1) SK65698A3 (es)
TR (1) TR199800897T2 (es)
TW (1) TW450978B (es)
WO (1) WO1997019104A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034283A2 (en) * 2000-10-27 2002-05-02 Novartis Ag Vegh inhibitors and their use
AU2005244249A1 (en) * 2004-03-17 2005-11-24 Novartis Vaccines And Diagnostics, Inc. Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (TFPI)
EP3774850A1 (en) 2018-03-29 2021-02-17 Kezar Life Sciences Cdp protein secretion inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3832059A1 (de) * 1988-09-21 1990-03-29 Howaldtswerke Deutsche Werft Tauchtiefengesteuerte ausblasventil-einrichtung
DE3832362A1 (de) * 1988-09-23 1990-03-29 Sandoz Ag Neue cyclopeptolide, verfahren zu ihrer herstellung und ihre verwendung
AT396108B (de) * 1991-08-21 1993-06-25 Biochemie Gmbh Neues verfahren und neue zwischenprodukte zur herstellung von 7-aminocephalosporansaeurederivaten
JPH07109299A (ja) * 1993-10-13 1995-04-25 Shionogi & Co Ltd 抗ｈｉｖ物質ペスタヒビン及びその誘導体
CN1116304C (zh) * 1994-07-27 2003-07-30 诺瓦蒂斯有限公司 有机化合物
US20040219569A1 (en) * 1999-07-06 2004-11-04 Fruma Yehiely Gene identification method

Also Published As

Publication number Publication date
MY115877A (en) 2003-09-30
SK65698A3 (en) 1998-11-04
HUP9903810A2 (hu) 2000-04-28
CA2237157C (en) 2009-04-07
WO1997019104A1 (en) 1997-05-29
AU712900B2 (en) 1999-11-18
IL124310A0 (en) 1998-12-06
PL186010B1 (pl) 2003-09-30
CN1202904A (zh) 1998-12-23
JP2000502992A (ja) 2000-03-14
CA2237157A1 (en) 1997-05-29
BR9611619B1 (pt) 2010-08-10
PL326755A1 (en) 1998-10-26
KR19990071533A (ko) 1999-09-27
MX9804048A (es) 1998-09-30
DE69628323D1 (en) 2003-06-26
AR012286A1 (es) 2000-10-18
EP0866801A1 (en) 1998-09-30
ES2200079T3 (es) 2004-03-01
HUP9903810A3 (en) 2001-04-28
RU2171260C2 (ru) 2001-07-27
TR199800897T2 (xx) 1998-08-21
CO4770985A1 (es) 1999-04-30
NO982280D0 (no) 1998-05-19
DE69628323T2 (de) 2004-08-19
CN1125079C (zh) 2003-10-22
US6011136A (en) 2000-01-04
NO982280L (no) 1998-05-19
EP0866801B1 (en) 2003-05-21
ATE240972T1 (de) 2003-06-15
NZ322909A (en) 1999-07-29
AU7694696A (en) 1997-06-11
TW450978B (en) 2001-08-21
BR9611619A (pt) 1999-03-30
CZ154998A3 (cs) 1998-08-12
JP3463691B2 (ja) 2003-11-05

Similar Documents

Publication Publication Date Title
Gowen et al. Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro.
FI943805A0 (fi) Substituoituja adeniinijohdannaisten käyttö multippeliskleroosin hoitoon
ES554688A0 (es) Procedimiento para la obtencion de esteres del acido (met)-acrilico
DE69331550T2 (de) Klonierung und expression von biologisch aktiver alpha-galaktosidase a
ES2190503T3 (es) Heterociclos de 5 anillos en calidad de inhibidores de la adhesion de leucocitos y antagonistas de vla-4.
DE69330459D1 (de) Verbindungen zur behandlung von allergischen und entzündlichen erkrankungen
ES2164717T3 (es) Compuestos triciclicos de sulfonamida utiles para inhibir la funcion de la proteina-g y para el tratamiento de enfermedades proliferativas.
FR2644178B1 (fr) Micro-organisme de l'espece bacillus coagulans et procede utilisant ce micro-organisme pour produire de l'acide l(+)lactique optiquement pur
NO177428C (no) Anvendelse av salter av metaller med carboxylsyrer for stabilisering av organopolysiloxanmasser
FI844929L (fi) Foerfarande foer racematavspaltning av bicykliska imino- -karboxylsyraestrar.
PE22998A1 (es) Ciclopeptolidos
DE69433424D1 (de) Pflanzen mit modifizierter reaktion auf ethylen
ID22049A (id) Komposisi-komposisi yang mengandung enzim pelepas reseptor faktor nekrosis tumor yang diisolasi dan metode pembuatannya
DE68928710T2 (de) T-Zellen-Wachstumsfaktor
DE69233451D1 (de) Ein verfahren zur herstellung therapeutisch wirksamer bruchstücke von von willebrand-faktor
DK514988D0 (da) Fremgangsmaade til industriel syntese af (2s,3as,7as)-2-carboxyperhydroindol
ATE258933T1 (de) Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie
ES8704754A1 (es) Un procedimiento para la preparacion de composiciones de un acido amino hidrocarbil sulfonico n-acilado o una sal del mismo.
Ichikawa et al. Co-expression of VRL-1 and calbindin D-28k in the rat sensory ganglia
UA26443A (uk) Похідhі 20,21-диhоребурhамеhіhу, їх рацемати або оптичhі ізомери, або їх адитивhі солі з оргаhічhими кислотами, що мають hоотропhі та аhтидепресивhі властивості
ES2093984T3 (es) Procedimiento para la obtencion fermentativa de acido 2-hidroxifenilacetico.
Kuca-Warnawin et al. P116 Basic characteristics of adipose-derived mesenchymal stem cells of ankylosing spondylitis patients
DK0503546T3 (da) Fremgangsmåde til biologisk rensning af vand
ATE85893T1 (de) Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis.
Nuki The Effects of Interleukin-1 on Cartilage and Bone

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed